Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30921384 | 0.89 | PYCR1 (0.56) | PYCR1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL313713 | 0.84 | CRHBP (0.48) | PYCR1ALDH1A1LMNASIGMAR1CSF1R | |
| SCHEMBL3086988 | 0.77 | NPC1 (0.44) | ALDH1A1LMNASIGMAR1KMT2ACSF1R | |
| SCHEMBL30774861 | 0.76 | SMN1; SMN2 (0.57) | ALDH1A1LMNAKMT2AMEN1CSF1R | |
| SCHEMBL1097545 | 0.76 | PYCR1 (0.66) | PYCR1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2106916 | 0.76 | NPC1 (0.56) | TSHRALDH1A1SIGMAR1KMT2AMEN1 | |
| SCHEMBL13162814 | 0.76 | SIRT6 (0.47) | ALDH1A1LMNAKMT2AMEN1KDM4E | |
| SCHEMBL3087992 | 0.74 | POLB (0.76) | CYP1A2CYP2C19TSHRALDH1A1POLB | |
| SCHEMBL3085819 | 0.74 | SIGMAR1 (0.48) | TSHRALDH1A1LMNASIGMAR1 | |
| SCHEMBL8491801 | 0.73 | CRHBP (0.54) | PYCR1TSHRSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765803-B1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| US-7799824-B2 | Quaternary salt CCR2 antagonists | ORAPHARMA, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799824-B2 | Quaternary salt CCR2 antagonists | ORAPHARMA, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799824-B2 | Quaternary salt CCR2 antagonists | ORAPHARMA, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-1765803-A1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-28 | — | — | EP | disclosed |
| US-20060293379-A1 | Quaternary salt CCR2 antagonists | KENVUE BRANDS LLC | 2006-12-28 | — | — | US | disclosed |
| WO-2006012135-A1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA, N. V. (BE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293379-A1 | Quaternary salt CCR2 antagonists | CCR2, CCR1, CXCR2 | PYCR1 1572/4885CYP1A2 2524/4885CYP2D6 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.